Jayson Pharma Ltd.

Dermin 6%+3%Benzoic Acid & Salicylic Acid is indicated for fungal infections, athlete's foot, barber's itch.Theropeutic ClassOther Antifungal preparationsPharmacologyBenzoic acid: Elicits weak antifungal and antibacterial properties; also helps acidify urine.Salicylic acid: It has a potent keratolytic action and a slight antiseptic action when applied topically. It softens and destroys the stratum corneum by increasing endogenous hydration which causes the horny layer of the skin to swell, soften, and then desquamate. At high concentrations, salicylic acid has a caustic effect. It also possesses weak antifungal and antibacterial activity.Dosage & Administration of Dermin 6%+3%Apply locally on the affected area 2-3 times per day.Dosage of Dermin 6%+3%Apply locally on the affected area 2-3 times per day.Interaction of Dermin 6%+3%It is not known if this interacts with other topical medications applied to the treatment area. The use of this drug with other topical drugs has not been studied.ContraindicationsHypersensitivity.Side Effects of Dermin 6%+3%Irritation, sensitivity, excessive drying; systemic effects on prolonged use.Pregnancy & LactationPregnancy Category-C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risksPrecautions & WarningsNot for prolonged use in high concentrations and on large areas of the body. Avoid broken skin, mouth, eyes, mucous membranes and anogenital region.Drug ClassesOther Antifungal preparationsMode Of ActionBenzoic acid: Elicits weak antifungal and antibacterial properties; also helps acidify urine.Salicylic acid: It has a potent keratolytic action and a slight antiseptic action when applied topically. It softens and destroys the stratum corneum by increasing endogenous hydration which causes the horny layer of the skin to swell, soften, and then desquamate. At high concentrations, salicylic acid has a caustic effect. It also possesses weak antifungal and antibacterial activity.PregnancyPregnancy Category-C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

KT 100 mlKT 100 ml is indicated in- Replacement of potassium deficit Diuretic (Potassium losing)-induced hypokalaemia Hypokalaemia from renal potassium wasting Hypokalaemia from gastrointestinal losses Hypochloraemic alkalosis associated with hypokalaemia Theropeutic ClassElectrolytes preparations, Oral electrolytes preparationsPharmacologyPotassium chloride is a major cation of the intracellular fluid. It plays an active role in the conduction of nerve impulses in the heart, brain and skeletal muscle; contraction of cardiac skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism and gastric secretion.Dosage & Administration of KT 100 mlOral:?Dosage must be adjusted to the individual needs of each patient. Adults: In severe deficiencies 3-6 tablets or 4-8 teaspoonful or 25-50 mmol per day orally in divided doses for some days with fruit juice, sweet or plain water. Children: ?-1 teaspoonful twice daily or 1-3 mmol/kg body weight a day in several divided doses. Patient should take Potassium chloride with meals.Intravenous:?Severe acute hypokalaemia: Adult: If serum potassium level >2.5 mEq/L, give at a rate not exceeding 10 mEq/hr in a concentration of up to 40 mEq/L. Max dose: 200 mEq/24 hr. If serum potassium level <2 mEq/L, may infuse at a rate of up to 40 mEq/hr. Continuous cardiac monitoring is essential. Max dose: 400 mEq/24 hr. 75 mg KCl equivalent to 1 mmol K+Dosage of KT 100 mlOral dose: It should be taken with or after meals with plenty of fluid (water/fruit juice). Typical doses for the prevention of hypokalaemia may be upto 50 mmol (about 37.5 mL) daily by mouth. Oral treatment may be suitable in some cases of hypokalaemia and similar doses to those used for prevention may be adequate in mild potassium deficiency. However, higher doses may be needed in more severe deficiency.Parenteral dose: Intravenous administration may be required in acute hypokalaemia. One ampoule (10 mL) i.e. 1.5 gm (20 mmol k+) may be added to 500 mL of sodium chloride or glucose intravenous infusion and given slowly over 2 to 3 hours with specialist advice and ECG monitoring in difficult cases. Repeated measurements of potassium are necessary to determine whether further infusions are required and to avoid the development of hyperkalaemia. This is especially liable to occur in renal impairment.Interaction of KT 100 mlCombined treatment with the following increase the risk of hyperkalaemia: Angiotensin-converting enzyme inhibitors, cyclosporin, NSAIDs, beta-blockers, heparin, digoxin, potassium-sparing diuretics.ContraindicationsHypersensitivity to potassium administration e.g. hyperkalaemic periodic paralysis, congenital paramyotonia, marked renal failure (even when not yet associated with manifest hyperkalaemia), untreated Addison's disease, hyporeninaemic hypoaldosteronism, acute dehydration, hyperkalaemia and conditions involving extensive cell destruction (e.g. severe burns). In case of metabolic acidosis, the hypokalaemia should be treated not with KT 100 ml.Side Effects of KT 100 mlExcessive administration of potassium leads to development of hyperkalaemia, the symptoms of which include paraesthesia of the extremitis, muscle weakness, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. Pain or phlebitis may occur during I.V. administration of solutions containing about 30 mmol or more potassium per litre. Nausea, vomiting, diarrhoea and abdominal cramps may occur following oral administration.Pregnancy & LactationCategory C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.Precautions & WarningsIt should be administered with caution to patients with renal or adrenocortical insufficiency, cardiac disease, acute dehydration, heat cramps, extensive tissue destruction as occurs with severe burns, or to patients receiving potassium-sparing diuretics. Excessive use of potassium-containing salt substitutes or concurrent administration with potassium supplements may lead to accumulation of potasssium especially in patients with renal insufficiency. Attention should be paid to the concurrent use of other drugs that either contain potassium or have the potential for hyperkalaemia. Treatment should be discontinued if severe nausea, vomiting or abdominal distress develops.Storage ConditionsStore below 25?C in a dry place, away from light. Keep out of the reach of children.Drug ClassesElectrolytes preparations, Oral electrolytes preparationsMode Of ActionKT 100 ml is used for the treatment of hypokalaemia and of potassium deficiency states. Potassium ion is the principal intracellular cation of most body tissues. It participates in a number of essential physiological processes, including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function.PregnancyAs a general rule, no drugs should be taken during the first three months of pregnancy and the risks & benefits of taking drugs should be carefully considered throughout pregnancy. There are no contraindications to breastfeeding while taking potassium salts.Pediatric UsesUse in children: No special precautions are required.

Meforex 500 mgTreatment of type 2 diabetes mellitus, particularly in overweight patients when dietary management and exercise alone does not result in adequate glycaemic control. In adults: Metformin may be used as monotherapy or in combination with other oral antidiabetic agents or with insulin. ... Read moreTreatment of type 2 diabetes mellitus, particularly in overweight patients when dietary management and exercise alone does not result in adequate glycaemic control. In adults: Metformin may be used as monotherapy or in combination with other oral antidiabetic agents or with insulin. In children from 10 years of age and adolescents: Metformin may be used as monotherapy or in combination with insulin. A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure.Theropeutic ClassBiguanidesPharmacologyMetformin is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.Dosage & Administration of Meforex 500 mgMetformin immediate release tablet: Dosage of Meforex 500 mg must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. Adult: The usual starting dose of Metformin is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. For those patients requiring additional glycemic control, Glucomin may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals. Children: The usual starting dose of Metformin is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses. Metformin extended release tablet: Swallow Metformin XR tablet whole and never crush, cut or chew. Adult: The usual starting dose of Metformin XR is 500 mg once daily with the evening meal. Dose should be increased in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal, alternatively increased to 1000 mg twice daily taken with meal. Patient receiving Metformin immediate release tablet may be switched to Metformin extended release tablet up to a maximum recommended daily dose. Children: Metformin extended release tablet has not been studied in children. Renal impaired patient: Do not use Metformin in patients with eGFR below 30 mL/min/1.73 m2. Asses risk/benefit of counting if eGFR falls below 45 mL/min/1.73 m2. Dosage of Meforex 500 mgMetformin immediate release tablet: Dosage of Meforex 500 mg must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. Adult: The usual starting dose of Metformin is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. For those patients requiring additional glycemic control, Glucomin may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals. Children: The usual starting dose of Metformin is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses. Metformin extended release tablet: Swallow Metformin XR tablet whole and never crush, cut or chew. Adult: The usual starting dose of Metformin XR is 500 mg once daily with the evening meal. Dose should be increased in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal, alternatively increased to 1000 mg twice daily taken with meal. Patient receiving Metformin immediate release tablet may be switched to Metformin extended release tablet up to a maximum recommended daily dose. Children: Metformin extended release tablet has not been studied in children. Renal impaired patient: Do not use Metformin in patients with eGFR below 30 mL/min/1.73 m2. Asses risk/benefit of counting if eGFR falls below 45 mL/min/1.73 m2. Interaction of Meforex 500 mgCo-administration with Carbonic anhydrase (Topiramate, Zonisamide) may increase risk of lactic acidosis. Drugs (Ranolazine, Dolutegravir, Cimetidine) that reduce Metformin clearance may increase the accumulation of Metformin. Alcohol can potentiate the effect of Metformin on lactate metabolism.Contraindications Hypersensitivity to the active substance or to any of the excipients. Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis). Severe renal failure (GFR <30 mL/min). Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock. Acute or chronic disease, which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock, Hepatic insufciency, acute alcohol intoxication, alcoholism. Side Effects of Meforex 500 mgBlood and lymphatic system disorders: Not known: Hemolytic anemiaMetabolism and nutrition disorders: Very rare: Lactic acidosis. Decrease of vitamin B12 absorption with a decrease of serum levels during long-term use of metformin. Consideration of such etiology is recommended if a patient presents with megaloblastic anemia. Cases of peripheral neuropathy in patients with vitamin B12 deficiency have been reported in post-marketing experience (frequency not known)Nervous system disorders: Common: Taste disturbance. Not known: EncephalopathyGastrointestinal disorders: Very common: Gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. To prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. A slow increase of the dose may also improve gastrointestinal tolerability.Hepatobiliary disorders: Very rare: Isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.Skin and subcutaneous tissue disorders: Very rare: Skin reactions, such as erythema, pruritus, urticaria.Pregnancy & LactationPublished studies have not reported a clear association with Metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when Metformin was used during pregnancy.Lactation: Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. However, a decision on whether to discontinue breast-feeding should be made or taking into account the benefit of breast-feeding and the potential risk to adverse effect on the child.Precautions & WarningsMeforex 500 mg is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Metformin may lower vitamin B12 level. It also increases risk of hypoglycemia when use in combination with insulin or insulin secretagogue.Overdose Effects of Meforex 500 mgHypoglycemia has not been seen with Metformin doses up to 85 gm, although lactic acidosis has occurred in such circumstances. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and Metformin is hemodialysis.Storage ConditionsKeep below 30?C temperature, protected from light & moisture. Keep out of the reach of children.Drug ClassesBiguanidesMode Of ActionMetformin is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.PregnancyPregnancy: Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with an increased risk of congenital abnormalities and perinatal mortality. When the patient plans to become pregnant and during pregnancy, it is recommended that diabetes is not treated with metformin but insulin be used to maintain blood glucose levels as close to normal as possible, to reduce the risk of malformations of the foetus.Breastfeeding: Metformin is excreted into human breast milk. No adverse efects were observed in breastfed newborns/infants. However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breastfeeding should be made, taking into account the benefit of breastfeeding and the potential risk to adverse effects on the child.Pediatric UsesElderly: Due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary.Pediatric population: The diagnosis of type 2 diabetes mellitus should be confirmed before treatment with metformin is initiated. No effect of metformin on growth and puberty has been detected during controlled clinical studies of one-year duration but no long-term data on these specific points are available. Therefore, a careful follow-up of the effect of metformin on these parameters in metformin-treated children, especially prepubescent children, is recommended.Children aged between 10 and 12 years: Particular caution is recommended when prescribing to children aged between 10 and 12 years.Renal function: As metformin is excreted by the kidney, creatinine clearance (this can be estimated from serum creatinine levels by using the Cockcroft-Gault formula) should be determined before initiating treatment and regularly thereafter: At least annually in patients with normal renal function, At least two to four times a year in patients with creatinine clearance at the lower limit of normal and in elderly subjects. Decreased renal function in elderly subjects is frequent and asymptomatic. Special caution should be exercised in situations where renal function may become impaired, for example when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID). GFR should be assessed before treatment initiation and regularly thereafter. Metformin is contraindicate in patients with GFR<30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function.

Optichlor 1%Optichlor 1% is indicated in Ocular infections,?Bacterial meningitis, Anaerobic bacterial infections, Anthrax, Brain abscess, Ehrlichiosis, Gas gangrene, Granuloma inguinale, Infections caused by H. influenzae, Listeriosis, Plague, Psittacosis, Q fever, Severe gastroenteritis, Severe melioidosis, Severe systemic infections with Camphylobacter fetus, Tularaemia, Whipple's disease,?Otitis externaTheropeutic ClassEar Anti-Infectives & Antiseptics, Eye Anti-Infectives & Antiseptics, MacrolidesPharmacologyOptichlor 1% inhibits bacterial protein synthesis by binding to 50s subunit of the bacterial ribosome, thus preventing peptide bond formation by peptidyl transferase. It has both bacteriostatic and bactericidal action against H. influenzae, N. meningitidis and S. pneumoniae.Dosage & Administration of Optichlor 1%For Eye: Adults, children and infants (all age groups): One or two drops 4 to 6 times a day should be placed in the infected eyes. If necessary the frequency of dose can be increased. Treatment should be continued for approximately 7 days but should not be continued for more than three weeks without re-evaluation by the prescribing physician.For Ear: 2 to 3 drops into ear canal thrice or four times daily.Otic/Aural: Otitis externa:?Instill 2-3 drops of a 5% solution into the ear bid-tid.Oral:?Bacterial meningitis, Anaerobic bacterial infections, Anthrax, Brain abscess, Ehrlichiosis, Gas gangrene, Granuloma inguinale, Infections caused by H. influenzae, Listeriosis, Plague, Psittacosis, Q fever, Severe gastroenteritis, Severe melioidosis, Severe systemic infections with Camphylobacter fetus, Tularaemia, Whipple's disease: Adult:?50 mg/kg/day in 4 divided doses increased to 100 mg/kg/day for meningitis or severe infections due to moderately resistant organisms. Continue treatment after the patient's temperature has normalised for a further 4 days in rickettsial disease and 8-10 days in typhoid fever. Child:?Premature and full-term neonates: 25 mg/kg/day in 4 divided doses. Full-term infants >2 wk: 50 mg/kg/day in 4 divided doses. Children: 50 mg/kg/day in 4 divided doses increased to 100 mg/kg/day for meningitis or severe infections. Interaction of Optichlor 1%Decreased effects of iron and vitamin B12 in anaemic patients. Phenobarbitone and rifampin reduce efficacy of Optichlor 1%. Impairs the action of oral contraceptives.ContraindicationsHistory of hypersensitivity or toxic reaction to the drug; pregnancy, lactation; porphyria; parenteral admin for minor infections or as prophylaxis; preexisting bone marrow depression or blood dyscrasias.Side Effects of Optichlor 1%Oral: GI symptoms; bleeding; peripheral and optic neuritis, visual impairment, blindness; encephalopathy, confusion, delirium, mental depression, headache. Haemolysis in patients with G6PD deficiency.ophthalmic application: Hypersensitivity reactions including rashes, fever and angioedema. Ear drops: Ototoxicity.Pregnancy & LactationPregnancy?Category C.?Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.Precautions & WarningsImpaired renal or hepatic function; premature and full-term neonates. Monitor plasma concentrations to avoid toxicity.Storage ConditionsCap/susp: Store at temp not exceeding 30?C. Ophth/otic preparation: Store between 2-8?C. Do not freeze. Protect from light.

Povisep 10% w/vCream or ointment:Therapeutically: As an adjunct to systemic therapy in the following indications- Primary or secondary topical infections Infected surgical incisions Infected decubitus or stasis ulcers Pyodermas Secondarily infected dermatoses ... Read moreCream or ointment:Therapeutically: As an adjunct to systemic therapy in the following indications- Primary or secondary topical infections Infected surgical incisions Infected decubitus or stasis ulcers Pyodermas Secondarily infected dermatoses Infected traumatic lesions Prophylactically: To prevent microbial contaminations in burns, incisions and other topical lesions For degerming skin in hyperalimentation, the umbilical area or circumcision Its use for abrasions, minor cuts, and wounds prevents the development of infections and permits wound healing. Solution: For the prevention and treatment of surface infections as well as to degerm the skin, mucous membrane and hyperalimentation procedures For seborrhea For preoperative and postoperative scrubbing and washing of hospital operating room and equipments For preoperative prepping of operative site, including the vagina For disinfection of wounds, burns, lacerations and abrasions As a prophylactic anti-infective agent in house, hospital & office procedures Postoperative application to incisions to help prevent infection In oral moniliasis (thrush); bacterial and mycotic skin infections, decubitus & stasis ulcers As a preoperative swab in the mouth & throat Gargle & Mouthwash: It is a pleasantly flavoured solution which is used: For the treatment of acute mucosal infections of the mouth and pharynx. For oral hygiene prior to, during and after dental and oral surgery. Surgical Scrub: It is a golden surfactant solution, forms rich, golden lather which is used: As an antiseptic skin cleanser for preoperative and postoperative scrubbing and washing by surgeons and operation theatre staff and preoperative preparation of patients' skinPowder: It is used for topical application in the following indications: Superficial wounds, Minor cuts, Burns, Abrasions, Lacerations, In the treatment and prevention of infections.Ophthalmic Solution: Povidone is used for the symptomatic treatment of dry eye conditions including keratoconjunctivitis sicca. It is also given as a substitute for tear fluid in case of the unstable tear film or insufficient moistening of the eye surface.Theropeutic ClassIodine compounds (Anti-septic Preparations)PharmacologyPovidone-Iodine contains Povidone-Iodine which is a stable chemical complex of polyvinylpyrrolidone (PVP) and elemental iodine. Povidone-Iodine shows non-selective broad spectrum germicidal action and acts as bactericide (both gram-positive and gram negative), fungicide, virucide, sporicide, amebicide, insecticide and nematocide and is effective in dilute solution. Povidone-Iodine does not develop resistance in microorganisms. Povidone-Iodine is safer and easier to use than classic iodine preparations and has low systemic toxicity. Unlike iodine solutions, it is nonsensitizing and does not cause pain when applied to wounds or mucous membranes. Povidone-Iodine will not permanently stain skin, natural fibres or hard surfaces. Povidone-Iodine is less irritating to the skin than conventional iodine preparations.Dosage & Administration of Povisep 10% w/vPovidone-Iodine 5% or 6% Ointment: For the treatment of infection: Apply once or twice daily or at dressing changes for a maximum of 14 days. For the prevention of infection: Apply once or twice a week for as long as necessary. The affected skin should be cleaned and dried. Apply ointment to the affected area. May be covered with a dressing or bandage. Povidone-Iodine 1% Mouthwash Gargle: Adults and children over 6 years of age: Use undiluted or diluted with an equal volume of warm water. Gargle or rinse with up to 10 ml for up to 30 seconds without swallowing. Repeat up to four times daily for up to 14 consecutive days or as directed. Povidone-Iodine 10% Solution: Apply full strength as an antiseptic skin cleanser.Dosage of Povisep 10% w/vCream or ointment: For the treatment of infection: Apply once or twice daily or at dressing changes for a maximum of 14 days. For the prevention of infection: Apply once or twice a week for as long as necessary. The affected skin should be cleaned and dried and can be covered with a dressing or bandage. Solution: Apply full strength as often as needed as paint, spray, or wet soak. Maybe bandaged (where necessary).Gargle & Mouthwash: Adults and children over 6 years of age: Use undiluted or diluted with an equal volume of warm water. Gargle or rinse with up to 10 mL for up to 30 seconds without swallowing. Repeat up to four times daily, for up to 14 consecutive days, or as advised by the Registered Dental Surgeon/Physician.Surgical Scrub: For Preoperative and Postoperative washing by Operating Personnel: Wet hands and forearms with water. Pour about 5 mL of Povisep 10% w/v Surgical Scrub on the palm of the hand and spread over both hands and forearms. Without adding more water, rub the Scrub thoroughly over all areas for about five minutes. Use a brush if desired. Clean thoroughly under fingernails. Add a little water and develop copious suds. Rinse thoroughly under running water. Complete the wash by scrubbing with another 5 mL of Povisep 10% w/v Surgical Scrub in the same way. For Preoperative use on Patients: After the skin area is shaved, wet it with water. Apply Povisep 10% w/v Surgical Scrub (1 mL is sufficient to cover an area of 20-30 square inches), develop lather and scrub thoroughly for about five minutes. Rinse off by aid of sterile gauze saturated with water. For use in the Physician's Office: Use for washing whenever a germicidal soap is required. Powder: Apply a light dusting of powder to the affected area. When dry, this forms a protective antiseptic layer over the area treated. Or use as advised by the Registered Physician. There are no special dosage recommendations for children or elderly patients.Ophthalmic Solution: 1 drop 4 times daily or as required, depending upon the severity of the disease, to be instilled into the conjunctival sac.Interaction of Povisep 10% w/vIt exhibits interaction with strong alkali, sodium thiosulphate, sodium metabisulphite and thiomersal. Use with concurrent lithium therapy has been shown to exhibithypothyroidic effect.ContraindicationsIt can cause hypersensitivity reactions. Regular use in patients with thyroid disorders (in particular nodular colloid goitre, endemic goitre and Hashimoto's thyroiditis) or those receiving lithium therapy is to be avoided. In severely burnt patients serum iodide levels should be assessed due to possible hepatic and renal impairment. Povisep 10% w/v Powder should not be used in serious cavities and in Children under the age of 2 years.Side Effects of Povisep 10% w/vPovisep 10% w/v may cause hypersensitivity reactions and irritation of the skin and mucous membranes. The application of povidone Iodine to severe burns or to large areas otherwise denuded of skin may produce systemic adverse effects such as metabolic acidosis, hypernatraemia, and impairment of renal function. It may interfere with thyroid function tests.Pregnancy & LactationRegular use of Povidone-Iodine should be avoided in pregnant or lactating women as absorbed iodine can cross the placental barrier and can be secreted into breast milk. Although no adverse effects have been reported from limited use, caution should be recommended and therapeutic benefit must be balanced against possible effects of the absorption of iodine on fetal thyroid function and development. The use of Povidone-Iodine 1% Mouthwash Gargle in pregnant and lactating women should not use for more than 14 days.Precautions & WarningsCream or ointment: In case of deep or puncture wounds or serious burns, consult Registered Physician. If redness, irritation, swelling or pain persists or increases or if infection occurs, discontinue use and consult Registered Physician.Solution: In preoperative prepping, avoid 'pooling' beneath the patient. Prolonged exposure to wet solution may cause irritation or rarely, severe skin reactions. In case of deep or puncture wounds or serious burns, consult Registered Physician. If redness, irritation, swelling or pain persists or increases or if infection occurs, discontinue use and consult Registered Physician.Gargle & Mouthwash: Regular use should be avoided as prolonged use may lead to the absorption of a significant amount of iodine. Do not use for more than 14 days. If sores or ulcers in the mouth do not heal within 14 days seek dental or medical advice. It is also not for use in children under 6 years of age. Regular use should be avoided in patients on concurrent lithium therapy.Surgical Scrub: Special caution is needed when regular applications to broken skin are made to patients with pre-existing renal insufficiency. Regular use should be avoided in patients on concurrent lithium therapy. It can permanently discolor white gold jewellery and it is recommended that this type of jewellery should be removed before using this product.Powder: Care must be taken when used on known iodine sensitivity, although do not normally react to Povidone-Iodine. Excess powder can be washed off readily with warm water. It should be used directly from the container. Not to be administered internally.Ophthalmic Solution: Patients, who experience blurred vision after application of the eye drops, should not drive or use machinery until their vision has cleared. Contact lenses should not be worn during the instillation of the drug. After instillation, there should be an interval of at least 30 minutes before reinsertion.Storage ConditionsStore below 25?C. Do not freeze. Store in a cool and dry place, protected from light. Keep out of the reach of children. Do not touch the ophthalmic solution dropper tip to any surface as this may contaminate this preparation. Do not use it after one month of the first opening.Drug ClassesIodine compounds (Anti-septic Preparations)Mode Of ActionPovisep 10% w/v is a complex of iodine and an organic polymer, povidone. This polymerization makes Povisep 10% w/v superior to ordinary elemental iodine. It prolongs the germicidal activity of iodine by liberating elemental iodine slowly. Consequently it has a lower toxicity than elemental iodine. It gives rapid microbicidal activity against both Gram-positive and Gram-negative bacteria, protozoa, viruses and fungi/yeasts. It is also sporicidal. It is the only microbicide with this broad spectrum of activity. It is non-staining, exerts prolong germicidal action and is also active in the presence of soap, blood, serum, pus, mucosal secretions and water.PregnancyPovisep 10% w/v Cream, Solution & Powder are not recommended for use during pregnancy because of the possibility of absorption of sufficient iodine to affect the fetal thyroid. American Academy of Pediatrics considers that the use of Povidone-Iodine is usually compatible with breast feeding. Consult Registered Physician. Regular use of Gargle & Mouthwash and Surgical Scrub should also be avoided in pregnant and lactating women.There is no experience regarding the safety of the Povidone eye drops in human pregnancy or lactation. Administration during pregnancy and lactation is therefore not recommended, except for compelling reasons.

Silcream Silcream cream is indicated in- The topical prophylaxis against bacterial colonization and infection in burn wounds. The topical antibacterial management of certain contaminated or infection-prone wounds, other than burns. Theropeutic ClassTopical Antibiotic preparationsPharmacologyThe mechanism of Silcream 's antibacterial action has not been fully elucidated. After exposure to the drug, structural changes in the bacterial cell membrane occur, including distortion and enlargement of the cell and a weakening of the cell wall membrane. This is accompanied by reduced viability in sensitive strains. The Silcream molecule dissociates and the silver moiety is bound to the bacterial cells. It is believed that, after penetrating the cell wall, the silver moiety is attached to deoxyribonucleic acid (DNA) and prevents bacterial cell proliferation. There is approximately 100 times more DNA in mammalian cells than in bacterial cells. It is thought that the ratio of Silcream to bacterial DNA is sufficiently high to prevent bacterial division but the corresponding ratio to epithelial DNA is low enough not to block epithelial cell regeneration. The sulfadiazine moiety also provides a bacteriostatic action against sensitive organisms. In adults, up to 10% of the sulfadiazine may be absorbed and 60 to 85% of the absorbed amount is excreted in the urine. In children with 13% body surface area burns, the urinary sulfadiazine concentration was 31.8 mg/L.Dosage & Administration of Silcream The burn wounds are cleansed, and Silcream is applied over the burn wound. The burn areas should be covered with Silcream at all times. The cream should be applied once to twice daily to a thickness of approximately 1/16 inches or 1.5 mm. Whenever necessary; the cream should be reapplied to any areas from which it has been removed by patient activity. If individual patient requirements make dressings necessary, they may be used. Reapplication should be ensured immediately after hydrotherapy. Treatment with Silcream should be continued until satisfactory healing is occurred, or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.Dosage of Silcream The burn wounds are cleansed, and Silcream is applied over the burn wound. The burn areas should be covered with Silcream at all times. The cream should be applied once to twice daily to a thickness of approximately 1/16 inches or 1.5 mm. Whenever necessary; the cream should be reapplied to any areas from which it has been removed by patient activity. If individual patient requirements make dressings necessary, they may be used. Reapplication should be ensured immediately after hydrotherapy. Treatment with Silcream should be continued until satisfactory healing is occurred, or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.Interaction of Silcream Enzymatic debriding agents: Silver sulfadiazine may inactivate enzymatic debriding agents, thus the concomitant use of these compounds may be inappropriate. Oral hypoglycemic agents and phenytoin: In patients with large area burns where serum sulfadiazine levels may approach therapeutic levels, the action of oral hypoglycemic agents and phenytoin may be potentiated and it is recommended that blood levels be monitored. Cimetidine: In-patients with large area burns, it has been reported that co-administration of Cimetidine may increase the incidence of leukopenia.ContraindicationsIt is contraindicated in-patients who are hypersensitive to it or any of the other ingredients in the preparation. It should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of lifeSide Effects of Silcream Several cases of transient leukopenia have been reported in-patients receiving Silcream therapy. Other infrequently occurring events include skin necrosis, erythema multiform, skin discoloration, burning sensation, rashes, and interstitial nephritis.Pregnancy & LactationPregnancy Category B. This drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term. It is not known whether Silcream is excreted in human milk. A decision should be made, whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established.Precautions & WarningsGeneral: If hepatic and renal functions become impaired and elimination of drug decreases, accumulation may occur and discontinuation of this should be weighed against the therapeutic benefit being achieved. In considering the use of topical proteolytic enzymes in conjunction with it, the possibility should be noted that silver might inactivate such enzymes. Laboratory Tests: In the treatment of burn wounds involving extensive areas of the body, the serum sulfa concentrations may approach adult therapeutic levels (8 mg% to 12 mg%). Therefore, in these patients it would be advisable to monitor serum sulfa concentrations. Renal function should be carefully monitored and the urine should be checked for sulfa crystals.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesTopical Antibiotic preparationsMode Of ActionThe mechanism of Silcream 's antibacterial action has not been fully elucidated. After exposure to the drug, structural changes in the bacterial cell membrane occur, including distortion and enlargement of the cell and a weakening of the cell wall membrane. This is accompanied by reduced viability in sensitive strains. The Silcream molecule dissociates and the silver moiety is bound to the bacterial cells. It is believed that, after penetrating the cell wall, the silver moiety is attached to deoxyribonucleic acid (DNA) and prevents bacterial cell proliferation. There is approximately 100 times more DNA in mammalian cells than in bacterial cells. It is thought that the ratio of Silcream to bacterial DNA is sufficiently high to prevent bacterial division but the corresponding ratio to epithelial DNA is low enough not to block epithelial cell regeneration. The sulfadiazine moiety also provides a bacteriostatic action against sensitive organisms. In adults, up to 10% of the sulfadiazine may be absorbed and 60 to 85% of the absorbed amount is excreted in the urine. In children with 13% body surface area burns, the urinary sulfadiazine concentration was 31.8 mg/L.PregnancyPregnancy Category B. This drug should be used during pregnancy only if clearly justified, especially in pregnant women approaching or at term. It is not known whether Silcream is excreted in human milk. A decision should be made, whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established.

Spasmoson 10 mg??????? ??????????????? ???? ???????????????? ????, ????????? ????????? ??????? ????? ??? ????????? (smooth muscle) ??? ??? ????????????? (antispasmodic) ??????? ??????? ??????? ??????????????? ???????? ????????? ??????????? ?????????? ???? ??????-???????? ??????????? ??????? ??????? ???? ?????????? ?????????? ?????????? ??????????????? ??? ?????????? ??????? ??????????????? ??????? ?????????-??????????? ??????? ??? ????? ???? ??????? (billary) ????? ???????? ?????????? ?????????? ????????????? ???????????? ??? ????????, ????????????? ??????? ? ????? ????? ??? ?????????-???????? ??????????? ?? ??? ????????? ???????? ????????? ???????? ?????? ??? ???? ???? ??????? ??????????????? ??????? ??????? ??? ????Theropeutic ClassAnticholinergics (antimuscarinics)/ Anti-spasmodicsPharmacologyHyoscine competitively blocks muscarinic receptors and has central and peripheral actions. It relaxes smooth muscle and reduces gastric and intestinal motility.Dosage of Spasmoson 10 mg??????? ????- ??????? ??????: ?? ?????? ???? ??? ???? ?????????? ????????????? ???????? ???????? (menstruation) ????? ???????? ??????? ??????? ????? ??? ???? ??????? ???? ???? ??? ??? ????? ????? ?????? ??? ??????? ?? ??????? ????? ???? ???? ? ???? ?? ???? ???????: ?? ?????? ???? ?????? ???? ????????? ??????? ?????????? ??????? ??????- ?????????????: ?????????? ?? ??????? ????????? ???? ?????? ?????? ????? ?? ?????? (??? ?????????), ????????? ?? ???? ?? ????? ?? ??????? ??????? ???? ???? ??????????? ???????? ?? ?????? ??? ?? ?? ??????? ???? ???? Administration of Spasmoson 10 mgMany things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications.?If your doctor has recommended a dose different from the ones listed here,do not change the way that you are using the medication without consulting your doctor.Swallow the tablets whole with a glass of water. Do not crush or chew the tablets.It is important to use this medication exactly as prescribed by your doctor. If you miss a dose, skip the missed dose and continue with your regular dosing schedule.?Do not use a double dose to make up for a missed one.?If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.Interaction of Spasmoson 10 mgAdditive sedative effects with alcohol or other CNS depressants. Reduced effects with acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine).Contraindications?? ?? ????? ?????????? ?????? ????? ????? ???????? ?? ??????? ??????? ??? ???????? ???????? ??? ???????? ???? ??????? ???? ???? ?? ?? ???? ???????????? ??????? ???? ???????? ?????????? ?????? ????? ????????? ??????? ??????? ???????? ???????? ????????????? ?????? ????? ?? ?? ????? ???????? ?????? ????? ????????? ???? ??????? ??????? ?Side Effects of Spasmoson 10 mg??????? ??????????????? ?? ???????-????????????? ????? ?????? ??? ??????? ??????, ?????? ?? ?????? (dilatation), ???????-??????? ??????? ??????, ???????, ???? ??????? ??????, ????????????????? ??? ??????? ??????????????? ? ????????? ???? ???? ????????, ???, ???? ?????? (giddiness) ??? ??????????? ??? ?????Pregnancy & LactationPregnancy Category C. Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risksPrecautions & Warnings????????: ???????? ?????? ?????? ???? ???? ? ?????? ??????? ???? ??? ??????? ??? ???? ????? ?? ??? ???? ???????? ????? ?????????? ?????? ????? ????? ?? ???????? ??????? ???? ?????? ????????? ????? ???????? ???? ???? ??? ??? ?????????? ?????? ???? ???? ??????? ??????? ??? ????? ???? ???? ????????????: ???????????????, ?????????? ??????????? (insufficiency) ?? ?????? ??? ????????? ????????????? ???????? ?? ???? ?????????? ??? ??? ???????? ???? ???? ??? ?? ???????? ??????? ??????? ??? ????? ???????? ???????????????? ???????? ???? ?????????, ??? ??? ??????????????, ???????????? ? ???????????? ??? ????????????? ???????????????? ?????????? ???? ?????? ????????? ??? ?????????? ??????? ????? ???? ???? ?????? ? ?? ???????? ???????? ??????? ???? ??? ?? ?????? ?????? ????? ???????? ??? ?????Storage Conditions?????? ?????????? ?? ??????? ????? ??? ??? ???? ??????? ??????? ????? ??????? ????????? ??????????? ????????? ???????????? ???????? ???????????Drug ClassesAnticholinergics (antimuscarinics)/ Anti-spasmodicsPregnancy??????????? ????? ??? ???? ???????? ?????? ??? ???? ???????? ???? ??????? ???? ????